Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug 31;228(Suppl 2):S111-S116.
doi: 10.1093/infdis/jiad200.

Immune Status and SARS-CoV-2 Viral Dynamics

Yijia Li  1 , Carlee Moser  2 , Evgenia Aga  2 , Judith S Currier  3 , David A Wohl  4 , Eric S Daar  5 , Justin Ritz  2 , Alexander L Greninger  6 , Scott Sieg  7 , Urvi M Parikh  1 , Robert W Coombs  6 , Michael D Hughes  2 , Joseph J Eron  4 , Davey M Smith  8 , Kara W Chew  3 , Jonathan Z Li  9 ; ACTIV-2/A5401 Study Team
Collaborators, Affiliations
Clinical Trial

Immune Status and SARS-CoV-2 Viral Dynamics

Yijia Li et al. J Infect Dis. .

Abstract

Immunocompromised individuals are disproportionately affected by severe coronavirus disease 2019, but immune compromise is heterogenous, and viral dynamics may vary by the degree of immunosuppression. In this study, we categorized ACTIV-2/A5401 participants based on the extent of immunocompromise into none, mild, moderate, and severe immunocompromise. Moderate/severe immunocompromise was associated with higher nasal viral load at enrollment (adjusted difference in means: 0.47 95% confidence interval, .12-.83 log10 copies/mL) and showed a trend toward higher cumulative nasal RNA levels and plasma viremia compared to nonimmunocompromised individuals. Immunosuppression leads to greater viral shedding and altered severe acute respiratory syndrome coronavirus 2 viral decay kinetics. Clinical Trials Registration. NCT04518410.

Keywords: COVID-19; RNA; SARS-CoV-2; immunocompromise.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. K. W. C. receives research funding from Merck, Sharp & Dohme (paid to institution) and Amgen (research contract with institution); consultancy for Pardes Biosciences; honoraria to the author for continuing medical education presentations (not-for-profit organization) from the International Antiviral Society–USA (IAS-USA); and participation on a data and safety monitoring board (DSMB) or advisory board for the University of California, San Francisco (UCSF) (served as Chair of a safety monitoring committee for an investigator-initiated study where the sponsor is UCSF). E. S. D. receives consulting fees from Gilead Sciences, Merck, and GSK/ViiV; research support through the institution from Gilead Sciences and GSK/ViiV; participation on a DSMB or advisory board for Gilead and ViiV; and reports support from NIH. D. A. W. has received funding to institution to support research and honoraria for advisory boards and consulting from Gilead Sciences and grant or contracts from Lilly. J. Z. L. has consulted for AbbVie and received a research grant from Merck. J. J. E. is an ad hoc consultant to GSK/Vir Biotechnology and is data monitoring committee chair for Adagio phase 3 studies. J. S. C. has consulted for Merck and Co and reports a leadership or fiduciary role in other board, society, committee, or advocacy groups as a volunteer for the Board of Directors of the IAS-USA and the Foundation Board, Conference on Retroviruses and Opportunistic Infections. D. M. S. has consulted for Bayer Healthcare, Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, and Pharma Holdings; has grants or contracts from NIH (DK131532, AI169609, DA047039, AI036214, AI131385, AI100665, AI126620, funding provided to institution), the James B. Pendleton Charitable Trust John, and the Mary Tu Foundation, including payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events for Medscape (COVID treatment), American Institute continuing medical education (COVID treatment), and Kiadis; stock or stock options for Model Medicine, Linear Therapies, and Cv Biosciences; and receipt of equipment, materials, drugs, medical writings, gifts, or other services from the James B. Pendleton Charitable Trust. C. M. reports participation on a DSMB for BONE STAR. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Nasal RNA over time by immunocompromised status among participants on placebo. Only participants with day 0 severe acute respiratory syndrome coronavirus 2 RNA levels above the lower limit of quantification are shown. Abbreviations: LLOQ, lower limit of quantification; LOD, limit of detection; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
See this image and copyright information in PMC

References

    1. Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of “long persisters.” Curr Transplant Rep 2022; 9:209–18. - PMC - PubMed
    1. Choi B, Choudhary MC, Regan J, et al. . Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020; 383:2291–3. - PMC - PubMed
    1. Gandhi S, Klein J, Robertson AJ, et al. . De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun 2022; 13:1547. - PMC - PubMed
    1. Hensley MK, Bain WG, Jacobs J, et al. . Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study. Clin Infect Dis 2021:73:e815–21. - PMC - PubMed
    1. Li Y, Harrison LJ, Chew KW, et al. . Nasal and plasma SARS-CoV-2 RNA levels are associated with timing of symptom resolution in the ACTIV-2 trial of non-hospitalized adults with COVID-19. Clin Infect Dis 2023; 76:734–7. - PMC - PubMed

Publication types

Associated data